AbbVie (ABBV) Q2 2025: Ex-Humira Platform Surges 22%, Raising Full-Year Revenue Target by $1.5B
AbbVie’s ex-Humira portfolio delivered a decisive 22% sales lift, propelling a second upward revenue guidance revision and underscoring the company’s successful transition beyond its legacy blockbuster. Neuroscience and immunology drove broad-based outperformance, while aesthetics remained pressured by macro headwinds. With a robust late-stage pipeline and $1.5 billion in added revenue guidance since January, AbbVie signals durable growth levers into the next decade.
Summary
- Ex-Humira Franchise Momentum: Neuroscience and immunology platforms are now the primary growth engines, offsetting Humira erosion.
- Pipeline and Business Development: Strategic deal flow and late-stage R&D milestones expand AbbVie’s addressable markets.
- Guidance Raised Again: Upward revenue and EPS revisions reflect outperformance and confidence in core brands’ durability.
Performance Analysis
AbbVie’s Q2 results decisively outpaced expectations, driven by its ex-Humira portfolio, which grew 22% and now anchors the company’s growth narrative. Immunology, led by Skyrizi and Rinvoq, delivered robust double-digit gains, with Skyrizi alone on pace for over $17 billion in annual revenue and Rinvoq exceeding $8 billion. Neuroscience surged 24% operationally, propelled by strong volume growth in Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta. Oncology showed mixed results, with Imbruvica declining due to competitive pressures, but Venclexta and launches like Imrelus adding incremental upside.
Aesthetics remained a drag, with Botox Cosmetic and Juvederm both declining as macroeconomic headwinds and consumer sentiment weighed on demand. However, AbbVie’s commercial execution in core therapeutic areas and a disciplined approach to R&D and SG&A spending preserved high operating margins and enabled upward revisions to both revenue and adjusted EPS guidance for the year.
- Immunology Outperformance: Skyrizi and Rinvoq together now capture half of new Crohn’s patients and a third of ulcerative colitis initiations in the US, reflecting strong physician preference and patient share gains.
- Neuroscience Scale: Neuroscience is now AbbVie’s second largest and fastest-growing segment, with a clear path to industry leadership in 2026.
- Humira Decline Managed: Humira sales fell as expected with biosimilar competition, but the ex-Humira portfolio more than offset the loss, validating AbbVie’s transition strategy.
AbbVie’s portfolio breadth and operational discipline enabled a second consecutive guidance raise, with management now targeting $60.5 billion in 2025 revenue and adjusted EPS between $11.88 and $12.08.
Executive Commentary
"We are making excellent progress advancing our pipeline and adding more depth through strategic transactions that support our long-term growth. Based on our momentum through the first half of the year, we are raising guidance for the second time."
Rob Michael, Chairman and Chief Executive Officer
"Our updated revenue forecast includes the following approximate assumptions for several of our key products and therapeutic areas. In immunology, we now expect Skyrizy global revenues of $17.1 billion, an increase of $600 million, reflecting continued share gains in psoriasis and IBD."
Scott Runtz, Executive Vice President, Chief Financial Officer
Strategic Positioning
1. Immunology Leadership and Durability
Skyrizi, IL-23 inhibitor, and Rinvoq, JAK inhibitor, are now the dual anchors of AbbVie’s immunology franchise. Both drugs continue to take share across existing and new indications, with Skyrizi’s IBD launches (Crohn’s and ulcerative colitis) driving outsized growth. Head-to-head clinical data and broad label expansion create a high barrier for new entrants, and management sees substantial remaining headroom, especially in earlier-stage IBD adoption and new indications like alopecia areata.
2. Neuroscience as a Growth Engine
Neuroscience revenue grew 24% operationally, led by Vraylar, Botox Therapeutic, and migraine assets Ubrelvy and Qulipta. Volume is the primary growth driver, and AbbVie is investing in salesforce expansion and new launches (Vraylar, Tavapidon) to sustain leadership. The company expects to become the largest neuroscience player globally next year, supported by pipeline assets in Parkinson’s and Alzheimer’s disease.
3. Oncology Portfolio Evolution
Oncology remains a mixed story: Imbruvica faces ongoing CLL competition, but Venclexta and new launches like Imrelus (ADC for lung cancer) and early-stage ADCs and T-cell engagers add depth, especially in multiple myeloma and solid tumors. AbbVie’s focus on differentiated modalities, including trispecific antibodies and in vivo CAR-T, aims to secure long-term oncology relevance.
4. Aesthetics Navigates Macro Headwinds
Aesthetics sales declined 8% operationally, with Botox Cosmetic and Juvederm pressured by consumer sentiment and economic softness. Management attributes the downturn to chronic consumer wallet pressure, not share loss, and is doubling down on innovation (Trennabot E, a short-acting toxin) and patient activation campaigns to position for eventual recovery. The aesthetics channel is also seen as a strategic asset for future obesity therapies.
5. Pipeline Expansion and Business Development
Over 30 deals since 2024, including the Gubra amylin analog (obesity), Capstan in vivo CAR-T, ISB2001 trispecific myeloma antibody, and ADARx siRNA platform, highlight AbbVie’s commitment to securing future growth. The company is targeting early- and mid-stage assets with high differentiation potential, aiming to extend its growth runway beyond the current portfolio’s lifecycle.
Key Considerations
AbbVie’s Q2 reflects a business in successful transition, with strong commercial execution, pipeline progress, and disciplined capital allocation setting up multi-year visibility. However, near-term challenges remain in aesthetics and legacy franchises.
Key Considerations:
- Immunology Share Gains: Skyrizi and Rinvoq continue to expand across indications, but new competitors and biosimilar dynamics require watchful execution.
- Neuroscience Investment: AbbVie is scaling its commercial and R&D footprint in neuroscience, betting on volume-driven growth and new launches to offset any future patent cliffs elsewhere.
- Aesthetics Volatility: Persistent macro headwinds and shifting consumer preferences are weighing on aesthetics, with management signaling a longer recovery timeline but no loss of market share.
- Pipeline Optionality: Business development remains focused on platforms and assets that can deliver post-2030 growth, leveraging AbbVie’s strong cash flow and balance sheet.
- Tariff and Policy Exposure: Management highlighted insulation from near-term tariff changes due to US manufacturing, but flagged ongoing policy risk and the need for continued vigilance.
Risks
Key risks include continued pricing and access pressure in the US, especially as the IRA (Inflation Reduction Act) price negotiations expand and biosimilar competition accelerates Humira’s decline. Macroeconomic weakness could prolong the aesthetics recovery, while pipeline execution risk remains in oncology and next-generation immunology assets. Regulatory and trade policy uncertainty, particularly on tariffs and drug pricing, could disrupt cost structure or market access in future periods.
Forward Outlook
For Q3 2025, AbbVie guided to:
- Net revenues of approximately $15.5 billion
- Adjusted EPS between $3.24 and $3.28
For full-year 2025, management raised guidance:
- Total net revenues of $60.5 billion (up $1.5 billion since January)
- Adjusted EPS between $11.88 and $12.08
Management emphasized drivers including continued immunology and neuroscience share gains, resilience in oncology, and a neutral FX outlook. They highlighted a back-half pricing step-down in Skyrizi and ongoing investment in neuroscience and pipeline assets.
- Immunology and neuroscience will drive the bulk of incremental growth
- Aesthetics guidance remains conservative due to persistent macro uncertainty
Takeaways
AbbVie’s successful ex-Humira transition is now a proven reality, with immunology and neuroscience providing a durable growth base and the pipeline and BD activity extending the runway. Investors should monitor the pace of aesthetics recovery, competitive dynamics in immunology, and the translation of pipeline bets into future revenue streams.
- Portfolio Diversification Pays Off: AbbVie’s broad-based growth in immunology and neuroscience is offsetting legacy erosion and enabling upward guidance revisions.
- Disciplined Capital Deployment: Management’s focus on early- and mid-stage deals, US-based manufacturing, and operational leverage supports both near-term and long-term value creation.
- Watch Pipeline Execution: The next wave of launches and clinical milestones, especially in oncology and novel immunology modalities, will determine AbbVie’s trajectory post-2030.
Conclusion
AbbVie’s Q2 2025 marks a strategic inflection, with the ex-Humira franchise firmly established as the new growth engine and a robust pipeline and deal cadence extending visibility. While aesthetics remains challenged, the company’s operational discipline and R&D momentum position it for continued leadership in large, durable therapeutic categories.
Industry Read-Through
AbbVie’s results reinforce the industry shift toward diversified portfolios and the importance of late-stage innovation to offset patent cliffs and pricing headwinds. The company’s success with Skyrizi and Rinvoq underscores the value of broad label expansion and head-to-head clinical data in specialty markets. Persistent aesthetics softness signals broader consumer sensitivity in cash-pay healthcare, while ongoing business development reflects the sector’s race to secure next-generation assets in immunology, neuroscience, and oncology. Peers should take note of AbbVie’s US manufacturing focus amid tariff and policy uncertainty, and the accelerating need to balance near-term performance with long-term pipeline bets.